NDANASALPOWDER
Approved
Jan 2016
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
7
Data completeness
6/8 — Strong
ONZETRA XSAIL (sumatriptan succinate) by Currax Pharmaceuticals is 5-ht 1b/1d receptors. Approved for migraine disorders, migraine, migraine without aura. First approved in 2016.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ONZETRA XSAIL is a nasal powder formulation of sumatriptan succinate, a triptan indicated for acute treatment of migraine with or without aura. It works by agonizing 5-HT1B/1D receptors on intracranial blood vessels and trigeminal sensory nerves, causing cranial vasoconstriction and inhibiting pro-inflammatory neuropeptide release.
$0.509MPart D
Peak8.5 years to LOEProduct is at peak lifecycle with modest Part D claims, indicating niche positioning within a crowded migraine market.
Mechanism of Action
5-HT 1B/1D receptors. Sumatriptan presumably exerts its therapeutic effects in the treatment of migraine headache through agonist effects at the 5-HT 1B/1D receptors on intracranial blood vessels and sensory nerves of the trigeminal system, which result in cranial vessel constriction and inhibition…
Indications (3)
Worked on ONZETRA XSAIL at Currax Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.